Novo Nordisk A/S (NVO) Stock Forecast & Price Target
Novo Nordisk A/S · NYSE
$50.92+1.25 (+2.52%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Novo Nordisk A/S, 3 rate it Buy or better, 7 sit at Hold, and 2 rate it Sell or worse, a hold consensus. Targets span $41.00 to $73.50, a moderate spread. The average target of $57.92 sits 14% above the current $50.92. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $4.70 next quarter toward $21.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Hold
Strong Buy00%
Buy325%
Hold758%
Sell217%
Strong Sell00%
Based on 12 analysts giving stock ratings to Novo Nordisk A/S.
As of Jul, 3 of 11 firms rate NVO a Buy (6 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
NVO EPS & revenue forecast
EPS · NEXT QUARTER
$4.70
Range $4.49 – $5.09 · 3 analysts · +5% YoY
Next period, 3 analysts expect Novo Nordisk A/S to earn $4.70 a share (range $4.49 – $5.09), versus $4.50 a year earlier. Full-year consensus is $21.77, growing to $21.39 the year after.
REVENUE · NEXT QUARTER
$71.9B
Range $69.8B – $76.7B · 3 analysts · -4% YoY
Revenue is expected to reach $71.9B (range $69.8B – $76.7B), -4.1% year-over-year. Full-year consensus is $293.8B, rising to $300.2B next year.
Top analysts covering Novo Nordisk A/S
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NVO.
#1
Louise Chen
Cantor Fitzgerald · Rank #156
Buy
$160.00+214.2% to target
Overall win rate
43%
+ Follow
#2
Rajesh Kumar
HSBC
Hold
$54.00+6.0% to target
Coverage
—
+ Follow
#3
ED
Evan David Seigerman
BMO Capital
Hold
$46.00-9.7% to target
Coverage
—
+ Follow
#4
JQ
James Quigley
Goldman Sachs
Hold
$41.00-19.5% to target
Coverage
—
+ Follow
#5
TB
Thibault Boutherin
Morgan Stanley
Hold
$40.00-21.4% to target
Coverage
—
+ Follow
NVO stock forecast FAQ
What is NVO's average 12-month price target?+
The 4 analysts with a live target average $57.92 for Novo Nordisk A/S over the next 12 months, ranging from a $73.50 high to a $41.00 low.
Is NVO stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 12 analyst ratings, 3 are Buy or Strong Buy, 7 are Hold, and 2 are Sell or Strong Sell.
What are the highest and lowest price targets for NVO?+
The Street-high target is $73.50, and the Street-low is $41.00 (Goldman Sachs). The average of all 4 active targets is $57.92.
How many Wall Street analysts cover NVO?+
12 analysts have an active rating on Novo Nordisk A/S, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering NVO?+
Among analysts who currently cover NVO, Louise Chen of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #156). Their current call is Buy with a $160.00 target.
What is Novo Nordisk A/S's projected EPS for next quarter?+
The consensus estimate is $4.70 per share (range $4.49 – $5.09) across 3 analysts. Full-year EPS is projected at $21.77, rising to $21.39 the following year.
How much revenue is Novo Nordisk A/S expected to report next quarter?+
Consensus revenue is $71.9B (range $69.8B – $76.7B). Full-year revenue is projected at $293.8B, growing to $300.2B next year.
Have analysts been upgrading or downgrading NVO lately?+
As of Jul, 3 of 11 firms rate NVO a Buy (6 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NVO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
